SutroVax Stock

sutrovax.comBioTechFounded: 2013Funding to Date: $173.25MM

Developer of conjugate and novel complex antigen-based vaccines intended to prevent serious infectious diseases. The company's cell-free protein synthesis platform permits site-specific conjugation, enabling the creation of conjugate vaccines with the potential to deliver heightened immunity and broader protection.

Register for Details

For more details on financing and valuation for SutroVax, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Grant Pickering
Founder, President, Chief Executive Officer, Director & Board Member
Jeff Fairman Ph.D
Founder & Vice President of Research
Elaine Sun
Chief Financial Officer
Durga Bobba
Chief Business Officer
Paul Sauer
Vice President, Process Development & Manufacturing
Aron Stein Ph.D
Vice President, Regulatory Affairs and Quality Assurance

Board Members

Cristina Ghenoiu Ph.D
Longitude Capital
Francesco De Rubertis Ph.D
Medicxi
Grant Pickering
Heath Lukatch Ph.D
Kurt Von Emster
Abingworth Management
Moncef Slaoui Ph.D
Medicxi
Nisha Marathe Ph.D
Roche Venture Fund
Patrick Enright
Longitude Capital
Patrick Heron
Frazier Healthcare Partners
Peter Hirth Ph.D
Robert Hopfner Ph.D
NFLS - Pivotal
William Newell JD
Sutro Biopharma

Other companies like SutroVax in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM

News

SutroVax, a Foster City, Calif.-based biopharmaceutical company dedicated to the delivery of novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, closed a $110m Series D financing
SutroVax, a vaccine platform and development company, closed an $85m Series C financing. The round was led by TPG Growth, with participation from Medicxi and Foresite Capital and Abingworth, Longitude Capital, Frazier Health Care Partners, Pivotal bioVenture Partners, Roche Venture Fund, and CTI Life Sciences Fund